Navigation Links
AMT to Release Half Year 2008 Results on August 13, 2008

AMSTERDAM, The Netherlands, August 5 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it will release its financial results for the first half year of 2008 on Wednesday, August 13, 2008 at noon Central European Time (CET). To discuss these results, the company will conduct a conference call at 2:00 p.m. CET. Netherlands dial in: 0800-949-4517 (toll free); US dial in: +1-866-291-4166 (toll free); UK dial in: +44-207-107-0611. To listen to the conference call live via the internet, visit the investor relations portion of the AMT website at Please go to the website 15 minutes prior to the call to register, download and install the necessary audio software.

About Amsterdam Molecular Therapeutics

AMT has a unique gene therapy platform that to date appears to circumvent many if not all of the obstacles that have prevented gene therapy from becoming a mainstay of clinical medicine. Using adeno-associated viral (AAV) vectors as the delivery vehicle of choice for therapeutic genes, the company has been able to design and validate what is probably the first stable and scalable AAV production platform. As such, AMT's proprietary platform holds tremendous promise for thousands of rare (orphan) diseases, especially the ones that are caused by one faulty gene. AMT currently has a product pipeline with seven products at different stages of development.

SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Reminder: Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
2. Telik Announces 2008 Second Quarter Financial Release, Conference Call and Webcast
3. Huifeng Bio-Pharmaceutical (HFGB) to Release Second Quarter 2008 Earnings Results on August 15, 2008
4. A Statement From Larry Corey, MD, of the HIV Vaccine Trials Network Regarding the New HIV Infection Statistics Released Today by the Centers for Disease Control
5. Thermage, Inc. Announces Second Quarter 2008 Results Release Date and Conference Call
6. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
7. Webcast Alert: Transgenomic Inc. Announces Second Quarter 2008 Earnings Release Conference Call Webcast
8. 3SBio Inc. Schedules 2008 Second Quarter Earnings Release On Tuesday, August 12, 2008
9. NeoGenomics Schedules its Q2 2008 Earnings Release for July 31, 2008
10. American Pacific to Release Financial Results and Hold Fiscal 2008 Third Quarter Investor Teleconference
11. Zounds Hearing Develops and Releases Power BTE Hearing Aid
Post Your Comments:
(Date:11/27/2015)... PA (PRWEB) , ... November 27, 2015 , ... ... Technical Program that includes over 2,000 technical presentations offered in symposia, oral ... chemistry and applied spectroscopy, covers a wide range of applications such as, but ...
(Date:11/26/2015)... , England , November 26, 2015 ... Lightpoint Medical, an innovative medical device company specializing in imaging ... grant from the European Commission as part of the Horizon ... the company to carry out a large-scale clinical trial in ... -->      (Logo: , --> ...
(Date:11/25/2015)... 2015 2 nouvelles études permettent d ... les différences entre les souches bactériennes retrouvées dans la plaque ... êtres humains . Ces recherches  ouvrent une nouvelle ... en charge efficace de l,un des problèmes de ... .    --> 2 nouvelles études permettent ...
(Date:11/25/2015)... 2015  Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) ... CEO of Neurocrine Biosciences, will be presenting at the ... New York . .   ... 5 minutes prior to the presentation to download or ... will be available on the website approximately one hour ...
Breaking Biology Technology:
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
(Date:11/2/2015)... , Nov. 2, 2015  SRI International has ... to provide preclinical development services to the National Cancer ... SRI will provide scientific expertise, modern testing and support ... of preclinical pharmacology and toxicology studies to evaluate potential ... --> The PREVENT Cancer Drug Development Program is ...
(Date:10/29/2015)... health pioneer, Joseph C. Kvedar , MD, describes ... wellness, and the business opportunities that arise from it ... Healthy Things . Long before health and wellness ... vice president, Connected Health, Partners HealthCare, was creating a ... the hospital or doctor,s office into the day-to-day lives ...
Breaking Biology News(10 mins):